• LAST PRICE
    5.3000
  • TODAY'S CHANGE (%)
    Trending Down-0.2500 (-4.5045%)
  • Bid / Lots
    4.1500/ 10
  • Ask / Lots
    5.4400/ 1
  • Open / Previous Close
    5.4200 / 5.5500
  • Day Range
    Low 5.2800
    High 5.5000
  • 52 Week Range
    Low 3.9400
    High 7.9200
  • Volume
    3,065
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 5.55
TimeVolumeALIM
09:32 ET1565.42
09:54 ET1125.5
10:14 ET5325.28
11:42 ET1825.37
01:53 ET11005.3
02:40 ET2335.32
02:56 ET1005.3
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesALIM
Alimera Sciences Inc
37.1M
-2.1x
---
United StatesSABS
SAB Biotherapeutics Inc
29.3M
-1.3x
---
United StatesRMTI
Rockwell Medical Inc
13.6M
-0.1x
---
United StatesBIOQ
Bioqual Inc
69.3M
12.6x
+17.04%
United StatesCDTX
Cidara Therapeutics Inc
47.0M
-0.6x
---
United StatesOPNT
Opiant Pharmaceuticals Inc
54.3M
-2.6x
---
As of 2022-09-25

Company Information

Alimera Sciences, Inc. is a pharmaceutical company. The Company is engaged in commercialization and development of prescription ophthalmic pharmaceuticals. The Company focuses on diseases affecting the retina. The Company’s commercial product, ILUVIEN, is an intravitreal implant that treats patients by delivering a continuous microdose of the corticosteroid fluocinolone acetonide (FAc) in the eye, for up to 36 months. The Company’s product ILUVIEN is also used for the treatment of diabetic macular edema (DME). DME is a disease of retina that affects individuals with diabetes and can lead to severe vision loss and blindness. Its ILUVIEN is also used in the European Economic Area (EEA) to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). The Company commercially market ILUVIEN directly in the United States, Germany, United Kingdom, Portugal, and Ireland.

Contact Information

Headquarters
STE 290, 6120 WINDWARD PARKWAYALPHARETTA, GA, United States 30005
Phone
678-990-5740
Fax
678-990-5744

Executives

Non-Executive Chairman of the Board
C. Daniel Myers
President, Chief Executive Officer, Director
Richard Eiswirth
Chief Financial Officer
J. Phillip Jones
Chief Operating Officer, Senior Vice President - Commercial Operations Europe
Philip Ashman
Chief Marketing Officer, Senior Vice President - Corporate Communications and Managed Markets
David Holland

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$37.1M
Revenue (TTM)
$52.6M
Shares Outstanding
7.0M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.38
EPS
$-2.49
Book Value
$-0.38
P/E Ratio
-2.1x
Price/Sales (TTM)
0.7
Price/Cash Flow (TTM)
---
Operating Margin
-20.71%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.